retrospective analysis on the efficacy of 1-, 3-, and 6-month sustained-release (SR)
formulations of the gonadotropin-releasing hormone (GnRH) agonist triptorelin to suppress serum testosterone concentrations beyond current standards. Methods: Data of 920 male patients with PC enrolled in 9 prospective studies using testosterone serum concentrations as primary endpoint were pooled.
Patients aged 42-96 years had to be eligible for ADT and to be either naïve to hormonal treatment or have undergone appropriate washout prior to enrolment. Patients were treated with triptorelin SR formulations for 2-12 months.
Primary endpoints of this analysis were serum testosterone concentrations under treatment and success rates overall and per formulation, based on a testosterone target threshold of 20 ng/dl.
Results: After 1, 3, 6, 9, and 12 months of treatment, 79%, 92%, 93%, 90%, and 91% of patients reached testosterone levels \20 ng/dl, respectively. For the 1-, 3-, and 6-month formulations success rates ranged from 80-92%, from 83-93%, and from 65-97% with median (interquartile range) serum testosterone to initial ADT, which may result in a marked symptom reduction and prolonged survival, even if androgen-independent disease eventually develops [3] [4] [5] .
ADT was initially achieved surgically via bilateral orchiectomy. Gonadotropin-releasing hormone (GnRH) analogues emerging in the 1980s offered a novel approach to medical castration through suppression of the hypothalamic-pituitary-gonadal axis. One of these was triptorelin, which was shown to be up to 100 times more potent than the native GnRH in vitro and in vivo [6] [7] [8] . Its clinical development started in 1982 [3] and it was registered as the first GnRH agonist SR formulation worldwide in France in 1986.
Today, GnRH agonists are used worldwide for ADT [9] with survival rates similar to surgical castration [10] . They reduce serum testosterone to castrate levels via the decrease in pituitary gonadotropin secretion that follows down-regulation of the pituitary GnRH receptors [11] . The ensuing hypoandrogenic environment results in glandular and tumour shrinkage and in an increase of interglandular connective tissue [4, 12, 13] .
A testosterone level of 50 ng/dl (1.7 nmol/l) has been established as the standard castration threshold, which has been applied for over 40 years [14] . This threshold is widely accepted by regulatory authorities for the approval of GnRH analogues in the treatment of advanced PC [14, 15] and is also deemed adequate by the National Comprehensive Cancer Network (NCCN) [16] . The European Association of Urology (EAU) indeed also acknowledges the 50 ng/dl cut-off, but suggests 20 ng/dl (0.7 nmol/l) to be more appropriate as ''better results are repeatedly observed with lower levels compared to 50 ng/dl'' [17] .
In fact, there is growing evidence that the extent of testosterone suppression during ADT in hormone-sensitive PC patients predicts a lower risk of and shorter time to androgen-independent progression or castration-resistant PC (CRPC), although so far most studies have been retrospective and sample sizes were rather small [4, 11, 14, [18] [19] [20] . [4, 11, 14, [18] [19] [20] prompted us to re-examine testosterone data from nine phase II to IV studies, which is so far the largest analysis examining the efficacy of ADT at a cut-off level of 20 ng/dl [3, 9, 23] .
METHODS
This is a retrospective pooled analysis of nine prospective clinical studies on the efficacy of triptorelin 1-, 3-, and 6-month SR formulations for advanced PC with overall 920 evaluable patients. Four studies were randomised controlled phase II studies, two were randomised controlled phase III studies, and three were non-controlled phase II to IV studies (Table 1) (Fig. 1) . Overall, mean testosterone levels were maintained\20 ng/dl over study periods for all formulations except for the 6-month formulation at months 1 and 12 ( Fig. 2) because of single patients with exceptionally high levels (patient DEB-TRI6M-301-11-11613 with a value 422 ng/dl at month 1 and patient DEB-TRI6M-301-04-04602 with a value of 1213 ng/dl at month 12). Excluding those as outliers would result in mean values of 18.5 and 13.1 ng/dl, respectively.
Success rates per formulation in terms of the proportion of patients with testosterone\20 ng/dl ranged from 80-92%
for the 1-month formulation, 83-93% for the 3-month formulation, and 65-97% for the 6-month formulation (Fig. 1b) . The large majority of patients (89.7%) maintained stable low testosterone levels without two 
DISCUSSION
Our analysis of pooled testosterone data was based on a total of almost 1000 patients and is, so far, the largest of its kind. The great majority of patients treated with triptorelin were shown to achieve and maintain testosterone levels \20 ng/dl. This is in line with two other retrospective studies reassessing testosterone levels achieved by either orchiectomy [14] or by use of polymer-delivered subcutaneous leuprolide acetate formulations [26] .
Suppression of testosterone levels\20 ng/dl through ADT may thus be common and regardless of the formulation, although in our study, the testosterone decrease with the 6-month formulation appeared less rapid. However, this might have been due to a slightly different patient population as reflected by higher baseline BMI and testosterone levels. In fact, obese patients were reported to respond less to GnRH agonist treatment as compared to patients with normal BMI [27] . By contrast, the efficacy of the triptorelin 6-month formulation has recently been confirmed by a Danish study with patients under triptorelin showing significantly lower testosterone levels at months 3 and 6 than after subcapsular orchiectomy [28] .
Still, some limitations of our study may need to be considered: Safety data of the nine studies were not pooled and re-analysed as the overall safety profile of triptorelin treatment in PC has recently been confirmed to be well-established and consistent among formulations as well [29] . A more relevant limitation might be inherent to the retrospective design. Although all included clinical trials were quite homogeneous in terms of design, quality, enrolled populations, and analytical methods for the measurement of testosterone, they were of rather short 3-month, and TRI6M: 6-month formulation) are slightly offset to distinguish the corresponding measurements for each formulation duration and did therefore not allow for an assessment of the time to androgenindependent progression (AIP) or death. Thus, the clinical benefit of achieving testosterone levels\20 ng/dl could actually not be addressed. However, evidence is growing that such a benefit indeed exists, even though most studies so far have been retrospective as well and rather small in size.
In 73 PC patients on ADT followed up for 51 months (range 1-20 years) the lowest serum testosterone cut-off that was able to discriminate regarding AIP-free survival was 32 ng/dl (88 vs. 137 months; P\0.03).
However, only breakthrough testosterone increases[50, but not[20 ng/dl had a significant impact on AIP-free survival [18] . In 225 Japanese PC patients treated with combined androgen blockade and followed up for 45.8 months, multivariate analysis revealed nadir testosterone\20 ng/dl to be the most significant prognostic factor of overall survival [20] . The risk of death was also shown to significantly correlate with 6-month serum testosterone levels in 129 patients with metastatic PC treated with goserelin and followed up for 47.5 months (range 22-72) [11] . In the largest and longest retrospective study so far with 626 PC patients having received ADT for a median of 8 years, nadir testosterone levels\20 ng/dl were shown to be associated with longer times to disease progression [30] . Conversely, patients with a median testosterone level[20 ng/dl had a significantly higher risk of developing CRPC. Maximum testosterone levels C50 ng/dl (23% of patients) were associated with a significantly higher rate of progression to CRPC as compared to patients with maximum testosterone\20 ng/dl (27%) and patients with nadir testosterone levels C50 ng/dl (1%) had a significantly higher risk of dying from disease as compared to patients with nadir testosterone 20-50 (21%) and\20 ng/dl (78%).
By contrast, there have been only two prospective studies on the additional benefit of suppressing testosterone to lower serum thresholds or minimum levels: In 32 patients followed up for about 2 years, time to CRPC was significantly longer in those with 9-month testosterone\32 ng/dl as compared to those with[32 ng/dl; however no additional predictive value was found for those\20 ng/dl [4] . In the second study, 153 patients with advanced PC were treated with GnRH agonists for 65 months. Testosterone levels\20 ng/dl after 6 months were found to be associated with a significantly lower risk of death and a trend towards a lower risk of disease progression (P = 0.12) as compared to those[20 ng/dl [19] .
In conclusion, evidence is growing that 
